Synthesis and in vitro anti-HIV activity in human monocyte-derived macrophages of 2-oxothiazolidine-4(R)-carboxylic acid derivatives

Journal of Medicinal Chemistry

Volumn 42, Issue 23, 1999, Pages 4733-4740

  Oiry, Joël ^a   Puy, Jean Yves ^a   Mialocq, Patricia ^b   Clayette, Pascal ^b,c   Fretier, Philippe ^b   Jaccard, Philippe ^b   Dereuddre Bosquet, Nathalie ^b,c   Dormont, Dominique ^b   Imbach, Jean Louis ^a  

^a CNRS   (France)

^b INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^c SPI BIO   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; ACETYLCYSTEINE; ANTIVIRUS AGENT; CARBOXYLIC ACID DERIVATIVE; GLUTATHIONE; THIAZOLIDINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; OXIDATIVE STRESS; VIRUS REPLICATION;

ANTI-HIV AGENTS; HIV-1; HUMANS; MACROPHAGES; MONOCYTES; PYRROLIDONECARBOXYLIC ACID; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; THIAZOLIDINES;

EID: 0032752507     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980289j     Document Type: Article

References (47)

1. Meister, A.; Anderson, M. E. Glutathione. Annu. Rev. Biochem. 1983, 52, 711-760.
2. Staal, F. J. T.; Ela, S. W.; Roederer, M.; Anderson, M. T.; Herzenberg, L. A.; Herzenberg, L. A. Glutathione deficiency and human immunodeficiency virus infection. Lancet 1992, 339, 909-912.
3. Aukrust, P.; Svardal, A. M.; Müller, F.; Lunden, B.; Berge, R. K.; Ueland, P. M.; Froland, S. S. Increased levels of oxidized glutathione in CD4+ lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type 1 infection. Blood 1990, 86, 258-267.
4. Castagna, A.; Le Grazie, C.; Accordini A.; Giulidori, P.; Cavalli, G.; Bottiglieri, T.; Lazzarin, A. Cerebrospinal fluid S-adenosylmethionine (SAMe) and glutathione concentrations in HIV infection: effect of parenteral treatment with SAMe. Neurology 1995, 45, 1678-1683.
5. Helbling, B.; Von Overbeck, J.; Lauterburg, B. H. Decreased release of glutathione into the systemic circulation of patients with HIV infection. Eur. J. Clin. Invest. 1996, 26, 38-44.
6. Barré-Sinoussi, F.; Chermann, J. C.; Rey, F.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of T-lymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome (AIDS). Science 1983, 220, 868-871.
7. Eck, H.-P.; Mertens, T.; Rosokat, H.; Fätkenheuer, G.; Pohl, C.; Schrappe, M.; Daniel, V.; Näher, H.; Petzoldt, D.; Drings, P.; Dröge, W, T4+ cell numbers are correlated with plasma glutamate and cystine levels: association of hyper glutamatæmia with immunodeficiency in diseases with different ætiologies. Intern. Immunol. 1992, 4, 7-13.
8. Pace, G. W.; Leaf, C. D. The role of oxidative stress in HIV disease. Free Radical Biol. Med. 1995, 19, 523-528.
9. Marchetti, P.; Decaudin, D.; Macho, A.; Zamzami, N.; Hirsch, T.; Susin, S. A.; Kroemer, G. Redox regulation of apoptosis: impact of thiol oxidation status on mitochondrial function. Eur. J. Immunol. 1997, 27, 289-296.
10. Mihm, S.; Ennen, J.; Pessara, U.; Kurth, R.; Droge, W. Inhibition of HIV-1 replication and NF-κB activity by cysteine and cysteine derivatives. AIDS 1991, 5, 497-503.
11. Israël, N.; Gougerot-Pocidalo, M. A. Oxidative stress in human immunodeficiency virus infection. Cell. Mol. Life Sci. 1997, 53, 864-970.
12. Herzenberg, L. A.; De Rosa, S. C.; Dubs, J. G.; Rœderer, M.; Anderson, M. T.; Ela, S. W.; Deresinski, S. C.; Herzenberg, L. A. Glutathione deficiency is associated with impaired survival in HIV disease. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 1967-1972.
13. Kalebic, T.; Hinter, A.; Poli, G.; Anderson, M. E.; Meister, A.; Fauci, A. Suppression of human immunodeficiency virus expression in chronically infected monocytic cells by glutathione, glutathione ester, and N-acetylcysteine. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 986-990.
14. Bergamini, A.; Capozzi, M.; Ghibelli, L.; Salanitro, A.; Milanese, G.; Wagner, T.; Beninati, S.; Pesce, C. D.; Amici, C.; Rocchi, G. Cystamine potently suppresses in vitro HIV replication in acutely and chronically infected human cells. J. Clin. Invest. 1984, 93, 2251-2257.
15. Bergamini, A.; Ventura, A.; Mancino, G.; Capozzi, M.; Placido, R.; Salanitro, A.; Cappannoli, L.; Faggioli, E.; Stoler, A.; Rocchi, G. In vitro inhibition of the replication of human immunodeficiency virus type 1 by β-mercaptoethylamine (Cysteamine). J. Infect. Dis. 1996, 174, 214-218.
16. Kameoka, M.; Okada, Y.; Tobiume, M.; Kimura, T.; Ikuta, K. Intracellular glutathione as a possible direct blocker of HIV type 1 reverse transcription. AIDS Res. Hum. Retroviruses 1996, 12, 1635-1638.
17. Witschi, A.; Reddy, S.; Stofer, B.; Lauterburg, B. H. The systemic availability of oral glutathione. Eur. J. Clin. Pharmacol. 1992, 43, 667-669.
18. Borgstroem, L.; Kagedal, B.; Paulsen, O. Pharmacokinetics of N-acetylcysteine in man. Eur. J. Clin. Pharmacol. 1986, 34, 77-82.
19. Burgunder, J. M.; Varriale, A.; Lauterburg, B. H. Effects of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur. J. Clin. Pharmacol. 1989, 36, 127-131.
20. Williamson, J. M.; Meister, A. Stimulation of hepatic glutathione formation by administration of L-2-oxothiazolidine-4-carboxylate, a 5-oxo-L-prolinase substrate. Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 936-939.
21. Porta, P.; Aebi, S.; Summer, K.; Lauterburg, B. H. L-2-oxoxthiazolidine-4-carboxylic acid, a cysteine prodrug: pharmacokinetics and effects on thiols in plasma and lymphocytes in human. J. Pharmacol. Exp. Ther. 1991, 257, 331-334.
22. Boesgaard, S.; Aldershvile, J.; Poulsen, H. E.; Loft, S.; Anderson, M. E.; Meister, A. Nitrate tolerance in vivo is not associated with depletion of arterial or venous thiol levels. Circ. Res. 1994, 74, 115-120.
23. Kalayjian, R. C.; Skowron, G.; Emgushov, R.-T.; Chance, M.; Spell, S. A.; Borum, P. R.; Webb, L. S.; Mayer, K. H.; Jackson, J. B.; Yen-Lieberman, B.; Story, K. O.; Rowe, W. B.; Thompson, K.; Goldberg, D.; Trimbo, S.; Lederman, M. M. A phase I/II trial of intravenous L-2-oxothiazolidine-4-carboxylic acid (procysteine) in asymptomatic HIV-infected subjects. J. Acquired Immune Def. Syndr. 1994, 7, 369-374.
24. Auger, M. J.; Ross, J. A. The biology of the macrophage. In The macrophage; Lewid, C. E., McGee, J. O. Eds.; Oxford University Press: New York, 1992; pp 1-74.
25. Collman, R.; Hassan, N. F.; Walker, B.; Godfrey, B.; Cutilli, J.; Freidman, H.; Douglas, S. D.; Nathanson, N. Infection of monocyte-derived macrophages with human immunodeficiency virus type 1 (HIV-1). J. Exp. Med. 1989, 170.
26. Gendelman, H. E.; Orenstein, J. M.; Baca, L. M.; Weiser, B.; Burgers, H.; Kalter, D. C.; Meltzer, M. S. The macrophage in persistence and pathogensis of HIV infection. AIDS 1989, 3, 475-495.
27. Rœderer, M.; Ela, S. W.; Staal, F. J. T.; Herzenberg, L. A.; Herzenberg, L. A. N-Acetylcysteine: a new approach to anti-HIV therapy. AIDS Res. Hum. Retroviruses 1992, 8, 209-217.
28. Kaneko, T.; Shimokobe, T.; Ota, Y.; Toyokawa, E.; Inui, T.; Shiba, T. Synthesis and properties of 2-oxothiazolidine-4-carboxylic acid and its derivatives. Bull. Chem. Soc. Jpn. 1964, 37, 242-244.
29. Sheehan, J. C.; Daves, G. D., Jr. Facile alkyl-oxygen ester cleavage. J. Org. Chem. 1964, 29, 2006-2008.
30. Stelakatos, G. C.; Paganou, A.; Zervas, L. New methods in peptide synthesis. Part III. Protection of carbonyl group. J. Chem. Soc. 1966, 1191-1199.
31. Taylor-Papadimitriou, J.; Yovanidis, C.; Paganou, A.; Zervas, L. New methods in peptide synthesis. Part V. On α- and γ-diphenylmethyl and phenacyl esters of L-glutamic acid. J. Chem. Soc. 1967, 1830-1836.
32. Yang, C. C.; Merrifield, R. B. The β-phenacyl ester as a temporary protecting group to minimize cyclic imide formation during subsequent treatment of aspartyl peptides with HF. J. Org. Chem. 1976, 41, 1032-1041.
33. Hendrickson, J. B.; Kandall, C. The phenacyl protecting group for acids and phenols. Tetrahedron Lett. 1970, 5, 343-344.
34. Sheh, L.; Chen, B. L.; Chen, C. F. Synthesis of cyclic peptide homologues of glutathione as potential antitumor agents. Int. J. Pept. Res. 1990, 35, 55-62.
35. D'Ischia, M.; Prota, G.; Rotteveel, R. C.; Westerhof, W. A facile synthesis of 2-oxo-thiazolidines of biological interest. Synth. Commun. 1987, 17, 1577-1585.
36. König, W.; Geiger, R. New method for the synthesis of peptides: Activation of the carboxyl group with dicyclohexylcarbodiimide by using 1-hydroxybenzotriazoles as additives. Chem. Ber. 1970, 103, 788-798.
37. Dereuddre-Bosquet, N.; Clayette, P.; Martin, M.; Benveniste, O.; Fretier, P.; Jaccard, P.; Vaslin, B.; Lebeaut, A.; Dormont, D. Lack of IL-10 expression in monocyte-derived macrophages in response to in vitro infection by HIV-1 isolates. AIDS Res. Hum. Retroviruses 1997, 13, 9961-966.
38. Ho, W.-Z.; Douglas, S. D. Glutathiane and N-acetylcysteine suppression of human immnodeficiency virus replication in human monocyte/macrophages in vitro. AIDS Res. Hum. Retroviruses 1992, 8, 1249-1253.
39. Ho, W. Z.; Starr, S. E.; Sison, A.; Douglas, S. D. L-2-oxothiazolidine-4-carboxyclic acid inhibits human immunodeficiency virus type 1 replication in mononuclear phagocytes and lymphocytes. Clin. Diagn. Lab. Immunol. 1997, 4, 352-357.
40. Lioy, J.; Ho, W.-Z.; Cutilli, J. R.; Polin, R. A.; Douglas, S. D. Thiol suppression of human immunodeficiency virus type 1 replication in primary cord blood monocyte-derived macrophages in vitro. J. Clin. Invest. 1993, 91, 495-498.
41. Nottet, H. S. L. M.; van Asbeck, S.; de Graaf, L.; de Vos, N. M.; Visser, M. R.; Verhoef, J. Role for oxygen radicals in self-sustained HIV-1 replication in monocyte-derived macrophages: enhanced HIV-1 replication by N-acetylcysteine. J. Leukocyte Biol. 1994, 56, 702-707.
42. Chen, P.; Bauer, G.; Mitchell, J.; Factor, R.; Markham, R.; Schwartz, D. H. N-acetyl-cysteine and L-2-oxathiazolidine-4-carboxylic acid enhance contact-dependent growth of HIV in resting peripheral blood mononuclear cells (PBMC) in vitro and increase recovery of HIV from human-PBMC SCID mice. AIDS 1997, 11, 33-41.
43. Magnani, M.; Fraternale, A.; Casabianca, A.; Schiavano, G.; Chiarantini, L.; Palamara, A.; Ciriolo, M.; Rotilio, G.; Garaci, E. Antiretroviral effect of combined zidovudine and reduced glutathione therapy in murine AIDS. AIDS Res. Hum. Retroviruses 1997, 13, 1093-1099.
44. Fidgor, C. G.; Leemans, J. M. M.; Bont, W. S.; Vries, J. E. Theory and practice of centrifugal elutriation (CE). Factors influencing the separation of human blood cells. Cell. Biophys. 1983, 5, 105-118.
45. Gartner, S.; Markovits, P.; Markovitz, D. M.; Kaplan, M. H.; Gallo, R. C.; Popovic, M. The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986, 233, 215-219.
46. Kärber, G. Beitag Zur Kollektiven Behandlung Pharmakologiaher Reihenvesuche. Arch. Exp. Pathol. Pharmakol. 1931, 162, 956-959.
47. Rey, F.; Spire, B.; Dormont, D.; Barré-Sinoussi, F.; Montagnier, L.; Chermann, J. C. Characterization of RNA dependent DNA polymerase of a new human T-lymphotropic retrovirus (lymphadenopathy associated virus). Biochem. Biophys. Res. Commun. 1984, 121, 126-133.